# SCORE Search Results Details for Application 10552515 and Search Result 20090316_151740_us-10-552-515-1_copy_157_933.oligo8.rag.



This page gives you Search Results detail for the Application 10552515 and Search Result 20090316_151740_us-10-552-515-1_copy_157_933.oligo8.rag.

Go Back to previous page

GenCore version 6.3


OM protein - protein search, using sw model

Run on: March 17, 2009, 20:56:54 ; Search time 133 Seconds
(without alignments)
4899.431 Million cell updates/sec

Title: US-10-552-515-1_COPY_157_933
Perfect score: 777
Sequence: 1 QQDVQDGNTTVHYALLSASW.....SELSSHWTPFTVPKASQLQQ 777

Scoring table: OLIGO
Gapop 60.0 , Gapext 60.0

Searched: 4548778 seqs, 838641292 residues

Word size : 8

Total number of hits satisfying chosen parameters: 11

Minimum DB seq length: 8
Maximum DB seq length: 10

Post-processing: Listing first 45 summaries

Database : A_Geneseq_200812:*
1: geneseqp:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

| Result No. | Score | % Query Match | Length | DB | ID | Description |
|---|---|---|---|---|---|---|
| 1 | 9 | 1.2 | 9 | 1 | ADT77668 | Adt77668 Splice va |
| 2 | 9 | 1.2 | 9 | 1 | ADT77673 | Adt77673 Splice va |
| 3 | 9 | 1.2 | 9 | 1 | ADT77670 | Adt77670 Splice va |
| 4 | 9 | 1.2 | 9 | 1 | ADT77671 | Adt77671 Splice va |
| 5 | 9 | 1.2 | 9 | 1 | ADT77666 | Adt77666 Splice va |
| 6 | 9 | 1.2 | 9 | 1 | ADT77669 | Adt77669 Splice va |
| 7 | 9 | 1.2 | 9 | 1 | ADT77672 | Adt77672 Splice va |
| 8 | 9 | 1.2 | 9 | 1 | ADT77667 | Adt77667 Splice va |
| 9 | 8 | 1.0 | 10 | 1 | AAG95042 | Aag95042 Human com |
| 10 | 8 | 1.0 | 10 | 1 | AAG97554 | Aag97554 Human com |
| 11 | 8 | 1.0 | 10 | 1 | AAG97553 | Aag97553 Human com |

ALIGNMENTS

RESULT 1
ADT77668
ID  ADT77668 standard; peptide; 9 AA.
XX
AC  ADT77668;
XX
DT  13-JAN-2005  (first entry)
XX
DE  Splice variant-novel gene expressed in prostate (SV-NGEP) epitope.
XX
KW  Splice variant-novel gene expressed in prostate; SV-NGEP; human;
KW  prostate cancer; cytostatic; gene therapy; immunotherapy; epitope.
XX
OS  Homo sapiens.
XX
PN  WO2004092213-A1.
XX
PD  28-OCT-2004.
XX
PF  05-APR-2004; 2004WO-US010588.
XX
PR  08-APR-2003; 2003US-0461399P.
XX
PA  (USSH ) US DEPT HEALTH & HUMAN SERVICES.
XX
PI  Pastan I,  Bera TK,  Lee B;
XX
DR  WPI; 2004-758338/74.
XX

PT New Splice Variant-Novel Gene Expressed in Prostate polypeptide or
PT encoding nucleic acid molecule for diagnosing, preventing or treating
PT cancer, especially prostate cancer.
XX
PS Disclosure; SEQ ID NO 5; 88pp; English.
XX
CC The present sequence is that of a predicted epitope of human splice
CC variant-novel gene expressed in prostate (SV-NGEP) ADT77664. The epitope
CC is predicted to bind HLA2-01 and was identified using an HLA binding
CC motif program. It corresponds to amino acids 170-178 of SV-NGEP.
CC Polypeptides comprising an immunogenic fragment of 8 consecutive amino
CC acids of SV-NGEP which specifically bind to an antibody that specifically
CC binds a polypeptide comprising amino acids 157-933 of SV-NGEP are
CC claimed. The invention provides methods for: detecting prostate cancer in
CC a subject by contacting a sample with an antibody that specifically binds
CC a SV-NGEP polypeptide and detecting the formation of an immune complex,
CC or detecting an increase in expression of SV-NGEP polypeptide or mRNA;
CC producing an immune response against a cell expressing SV-NGEP, for
CC example in a subject with prostate cancer, by administering SV-NGEP
CC polypeptide or polynucleotide to produce an immune response that
CC decreases growth of the prostate cancer; inhibiting the growth of a
CC malignant cell that expresses SV-NGEP by culturing cytotoxic T
CC lymphocytes (CTLs) with SV-NGEP to produce activated CTLs, and contacting
CC these with the malignant cell; and inhibiting the growth of a malignant
CC cell by contact with an antibody that specifically binds SV-NGEP, where
CC the antibody is linked to a chemotherapeutic agent or toxin.
XX
SQ Sequence 9 AA;

Query Match 1.2%; Score 9; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. No. 3.9e+06;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy         14 ALLSASWAV 22
              |||||||||
Db          1 ALLSASWAV 9
```

RESULT 2
ADT77673
ID ADT77673 standard; peptide; 9 AA.
XX
AC ADT77673;
XX
DT 13-JAN-2005 (first entry)
XX
DE Splice variant-novel gene expressed in prostate (SV-NGEP) epitope.
XX
KW Splice variant-novel gene expressed in prostate; SV-NGEP; human;

KW prostate cancer; cytostatic; gene therapy; immunotherapy; epitope.
XX
OS Homo sapiens.
XX
PN WO2004092213-A1.
XX
PD 28-OCT-2004.
XX
PF 05-APR-2004; 2004WO-US010588.
XX
PR 08-APR-2003; 2003US-0461399P.
XX
PA (USSH ) US DEPT HEALTH & HUMAN SERVICES.
XX
PI Pastan I, Bera TK, Lee B;
XX
DR WPI; 2004-758338/74.
XX
PT New Splice Variant-Novel Gene Expressed in Prostate polypeptide or
PT encoding nucleic acid molecule for diagnosing, preventing or treating
PT cancer, especially prostate cancer.
XX
PS Disclosure; SEQ ID NO 10; 88pp; English.
XX
CC The present sequence is that of a predicted epitope of human splice
CC variant-novel gene expressed in prostate (SV-NGEP) ADT77664. The epitope
CC is predicted to bind HLA2-01 and was identified using an HLA binding
CC motif program. It corresponds to amino acids 562-570 of SV-NGEP.
CC Polypeptides comprising an immunogenic fragment of 8 consecutive amino
CC acids of SV-NGEP which specifically bind to an antibody that specifically
CC binds a polypeptide comprising amino acids 157-933 of SV-NGEP are
CC claimed. The invention provides methods for: detecting prostate cancer in
CC a subject by contacting a sample with an antibody that specifically binds
CC a SV-NGEP polypeptide and detecting the formation of an immune complex,
CC or detecting an increase in expression of SV-NGEP polypeptide or mRNA;
CC producing an immune response against a cell expressing SV-NGEP, for
CC example in a subject with prostate cancer, by administering SV-NGEP
CC polypeptide or polynucleotide to produce an immune response that
CC decreases growth of the prostate cancer; inhibiting the growth of a
CC malignant cell that expresses SV-NGEP by culturing cytotoxic T
CC lymphocytes (CTLs) with SV-NGEP to produce activated CTLs, and contacting
CC these with the malignant cell; and inhibiting the growth of a malignant
CC cell by contact with an antibody that specifically binds SV-NGEP, where
CC the antibody is linked to a chemotherapeutic agent or toxin.
XX
SQ Sequence 9 AA;

Query Match 1.2%; Score 9; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. No. 3.9e+06;

Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy        406 KIYVSLAHV 414
              |||||||||
Db          1 KIYVSLAHV 9
```

RESULT 3
ADT77670
ID ADT77670 standard; peptide; 9 AA.
XX
AC ADT77670;
XX
DT 13-JAN-2005 (first entry)
XX
DE Splice variant-novel gene expressed in prostate (SV-NGEP) epitope.
XX
KW Splice variant-novel gene expressed in prostate; SV-NGEP; human;
KW prostate cancer; cytostatic; gene therapy; immunotherapy; epitope.
XX
OS Homo sapiens.
XX
PN WO2004092213-A1.
XX
PD 28-OCT-2004.
XX
PF 05-APR-2004; 2004WO-US010588.
XX
PR 08-APR-2003; 2003US-0461399P.
XX
PA (USSH ) US DEPT HEALTH & HUMAN SERVICES.
XX
PI Pastan I, Bera TK, Lee B;
XX
DR WPI; 2004-758338/74.
XX
PT New Splice Variant-Novel Gene Expressed in Prostate polypeptide or
PT encoding nucleic acid molecule for diagnosing, preventing or treating
PT cancer, especially prostate cancer.
XX
PS Disclosure; SEQ ID NO 7; 88pp; English.
XX
CC The present sequence is that of a predicted epitope of human splice
CC variant-novel gene expressed in prostate (SV-NGEP) ADT77664. The epitope
CC is predicted to bind HLA2-01 and was identified using an HLA binding
CC motif program. It corresponds to amino acids 557-565 of SV-NGEP.
CC Polypeptides comprising an immunogenic fragment of 8 consecutive amino
CC acids of SV-NGEP which specifically bind to an antibody that specifically
CC binds a polypeptide comprising amino acids 157-933 of SV-NGEP are

CC claimed. The invention provides methods for: detecting prostate cancer in
CC a subject by contacting a sample with an antibody that specifically binds
CC a SV-NGEP polypeptide and detecting the formation of an immune complex,
CC or detecting an increase in expression of SV-NGEP polypeptide or mRNA;
CC producing an immune response against a cell expressing SV-NGEP, for
CC example in a subject with prostate cancer, by administering SV-NGEP
CC polypeptide or polynucleotide to produce an immune response that
CC decreases growth of the prostate cancer; inhibiting the growth of a
CC malignant cell that expresses SV-NGEP by culturing cytotoxic T
CC lymphocytes (CTLs) with SV-NGEP to produce activated CTLs, and contacting
CC these with the malignant cell; and inhibiting the growth of a malignant
CC cell by contact with an antibody that specifically binds SV-NGEP, where
CC the antibody is linked to a chemotherapeutic agent or toxin.
XX
SQ Sequence 9 AA;

Query Match 1.2%; Score 9; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. No. 3.9e+06;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy        401 ILILSKIYV 409
              |||||||||
Db          1 ILILSKIYV 9
```

RESULT 4
ADT77671
ID ADT77671 standard; peptide; 9 AA.
XX
AC ADT77671;
XX
DT 13-JAN-2005 (first entry)
XX
DE Splice variant-novel gene expressed in prostate (SV-NGEP) epitope.
XX
KW Splice variant-novel gene expressed in prostate; SV-NGEP; human;
KW prostate cancer; cytostatic; gene therapy; immunotherapy; epitope.
XX
OS Homo sapiens.
XX
PN WO2004092213-A1.
XX
PD 28-OCT-2004.
XX
PF 05-APR-2004; 2004WO-US010588.
XX
PR 08-APR-2003; 2003US-0461399P.
XX
PA (USSH ) US DEPT HEALTH & HUMAN SERVICES.

XX
PI  Pastan I,  Bera TK,  Lee B;
XX
DR  WPI; 2004-758338/74.
XX
PT  New Splice Variant-Novel Gene Expressed in Prostate polypeptide or
PT  encoding nucleic acid molecule for diagnosing, preventing or treating
PT  cancer, especially prostate cancer.
XX
PS  Disclosure; SEQ ID NO 8; 88pp; English.
XX
CC  The present sequence is that of a predicted epitope of human splice
CC  variant-novel gene expressed in prostate (SV-NGEP) ADT77664. The epitope
CC  is predicted to bind HLA2-01 and was identified using an HLA binding
CC  motif program. It corresponds to amino acids 258-266 of SV-NGEP.
CC  Polypeptides comprising an immunogenic fragment of 8 consecutive amino
CC  acids of SV-NGEP which specifically bind to an antibody that specifically
CC  binds a polypeptide comprising amino acids 157-933 of SV-NGEP are
CC  claimed. The invention provides methods for: detecting prostate cancer in
CC  a subject by contacting a sample with an antibody that specifically binds
CC  a SV-NGEP polypeptide and detecting the formation of an immune complex,
CC  or detecting an increase in expression of SV-NGEP polypeptide or mRNA;
CC  producing an immune response against a cell expressing SV-NGEP, for
CC  example in a subject with prostate cancer, by administering SV-NGEP
CC  polypeptide or polynucleotide to produce an immune response that
CC  decreases growth of the prostate cancer; inhibiting the growth of a
CC  malignant cell that expresses SV-NGEP by culturing cytotoxic T
CC  lymphocytes (CTLs) with SV-NGEP to produce activated CTLs, and contacting
CC  these with the malignant cell; and inhibiting the growth of a malignant
CC  cell by contact with an antibody that specifically binds SV-NGEP, where
CC  the antibody is linked to a chemotherapeutic agent or toxin.
XX
SQ  Sequence 9 AA;

  Query Match             1.2%;  Score 9;  DB 1;  Length 9;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+06;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        102 ILFEILAKT 110
              |||||||||
Db          1 ILFEILAKT 9

RESULT 5
ADT77666
ID  ADT77666 standard; peptide; 9 AA.
XX
AC  ADT77666;
XX

DT 13-JAN-2005 (first entry)
XX
DE Splice variant-novel gene expressed in prostate (SV-NGEP) epitope.
XX
KW Splice variant-novel gene expressed in prostate; SV-NGEP; human;
KW prostate cancer; cytostatic; gene therapy; immunotherapy; epitope.
XX
OS Homo sapiens.
XX
PN WO2004092213-A1.
XX
PD 28-OCT-2004.
XX
PF 05-APR-2004; 2004WO-US010588.
XX
PR 08-APR-2003; 2003US-0461399P.
XX
PA (USSH ) US DEPT HEALTH & HUMAN SERVICES.
XX
PI Pastan I, Bera TK, Lee B;
XX
DR WPI; 2004-758338/74.
XX
PT New Splice Variant-Novel Gene Expressed in Prostate polypeptide or
PT encoding nucleic acid molecule for diagnosing, preventing or treating
PT cancer, especially prostate cancer.
XX
PS Disclosure; SEQ ID NO 3; 88pp; English.
XX
CC The present sequence is that of a predicted epitope of human splice
CC variant-novel gene expressed in prostate (SV-NGEP) ADT77664. The epitope
CC is predicted to bind HLA2-01 and was identified using an HLA binding
CC motif program. It corresponds to amino acids 427-435 of SV-NGEP.
CC Polypeptides comprising an immunogenic fragment of 8 consecutive amino
CC acids of SV-NGEP which specifically bind to an antibody that specifically
CC binds a polypeptide comprising amino acids 157-933 of SV-NGEP are
CC claimed. The invention provides methods for: detecting prostate cancer in
CC a subject by contacting a sample with an antibody that specifically binds
CC a SV-NGEP polypeptide and detecting the formation of an immune complex,
CC or detecting an increase in expression of SV-NGEP polypeptide or mRNA;
CC producing an immune response against a cell expressing SV-NGEP, for
CC example in a subject with prostate cancer, by administering SV-NGEP
CC polypeptide or polynucleotide to produce an immune response that
CC decreases growth of the prostate cancer; inhibiting the growth of a
CC malignant cell that expresses SV-NGEP by culturing cytotoxic T
CC lymphocytes (CTLs) with SV-NGEP to produce activated CTLs, and contacting
CC these with the malignant cell; and inhibiting the growth of a malignant
CC cell by contact with an antibody that specifically binds SV-NGEP, where
CC the antibody is linked to a chemotherapeutic agent or toxin.

```
XX
SQ   Sequence 9 AA;

  Query Match             1.2%;  Score 9;  DB 1;  Length 9;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+06;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        271 SLFMALWAV 279
              |||||||||
Db          1 SLFMALWAV 9


RESULT 6
ADT77669
ID   ADT77669 standard; peptide; 9 AA.
XX
AC   ADT77669;
XX
DT   13-JAN-2005  (first entry)
XX
DE   Splice variant-novel gene expressed in prostate (SV-NGEP) epitope.
XX
KW   Splice variant-novel gene expressed in prostate; SV-NGEP; human;
KW   prostate cancer; cytostatic; gene therapy; immunotherapy; epitope.
XX
OS   Homo sapiens.
XX
PN   WO2004092213-A1.
XX
PD   28-OCT-2004.
XX
PF   05-APR-2004; 2004WO-US010588.
XX
PR   08-APR-2003; 2003US-0461399P.
XX
PA   (USSH ) US DEPT HEALTH & HUMAN SERVICES.
XX
PI   Pastan I,  Bera TK,  Lee B;
XX
DR   WPI; 2004-758338/74.
XX
PT   New Splice Variant-Novel Gene Expressed in Prostate polypeptide or
PT   encoding nucleic acid molecule for diagnosing, preventing or treating
PT   cancer, especially prostate cancer.
XX
PS   Disclosure; SEQ ID NO 6; 88pp; English.
XX
CC   The present sequence is that of a predicted epitope of human splice
CC   variant-novel gene expressed in prostate (SV-NGEP) ADT77664. The epitope
```

CC is predicted to bind HLA2-01 and was identified using an HLA binding
CC motif program. It corresponds to amino acids 846-854 of SV-NGEP.
CC Polypeptides comprising an immunogenic fragment of 8 consecutive amino
CC acids of SV-NGEP which specifically bind to an antibody that specifically
CC binds a polypeptide comprising amino acids 157-933 of SV-NGEP are
CC claimed. The invention provides methods for: detecting prostate cancer in
CC a subject by contacting a sample with an antibody that specifically binds
CC a SV-NGEP polypeptide and detecting the formation of an immune complex,
CC or detecting an increase in expression of SV-NGEP polypeptide or mRNA;
CC producing an immune response against a cell expressing SV-NGEP, for
CC example in a subject with prostate cancer, by administering SV-NGEP
CC polypeptide or polynucleotide to produce an immune response that
CC decreases growth of the prostate cancer; inhibiting the growth of a
CC malignant cell that expresses SV-NGEP by culturing cytotoxic T
CC lymphocytes (CTLs) with SV-NGEP to produce activated CTLs, and contacting
CC these with the malignant cell; and inhibiting the growth of a malignant
CC cell by contact with an antibody that specifically binds SV-NGEP, where
CC the antibody is linked to a chemotherapeutic agent or toxin.
XX
SQ Sequence 9 AA;

Query Match 1.2%; Score 9; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. No. 3.9e+06;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy        690 LLAIRLAFV 698
              |||||||||
Db          1 LLAIRLAFV 9
```

RESULT 7
ADT77672
ID ADT77672 standard; peptide; 9 AA.
XX
AC ADT77672;
XX
DT 13-JAN-2005 (first entry)
XX
DE Splice variant-novel gene expressed in prostate (SV-NGEP) epitope.
XX
KW Splice variant-novel gene expressed in prostate; SV-NGEP; human;
KW prostate cancer; cytostatic; gene therapy; immunotherapy; epitope.
XX
OS Homo sapiens.
XX
PN WO2004092213-A1.
XX
PD 28-OCT-2004.
XX

PF 05-APR-2004; 2004WO-US010588.
XX
PR 08-APR-2003; 2003US-0461399P.
XX
PA (USSH ) US DEPT HEALTH & HUMAN SERVICES.
XX
PI Pastan I, Bera TK, Lee B;
XX
DR WPI; 2004-758338/74.
XX
PT New Splice Variant-Novel Gene Expressed in Prostate polypeptide or
PT encoding nucleic acid molecule for diagnosing, preventing or treating
PT cancer, especially prostate cancer.
XX
PS Disclosure; SEQ ID NO 9; 88pp; English.
XX
CC The present sequence is that of a predicted epitope of human splice
CC variant-novel gene expressed in prostate (SV-NGEP) ADT77664. The epitope
CC is predicted to bind HLA2-01 and was identified using an HLA binding
CC motif program. It corresponds to amino acids 403-411 of SV-NGEP.
CC Polypeptides comprising an immunogenic fragment of 8 consecutive amino
CC acids of SV-NGEP which specifically bind to an antibody that specifically
CC binds a polypeptide comprising amino acids 157-933 of SV-NGEP are
CC claimed. The invention provides methods for: detecting prostate cancer in
CC a subject by contacting a sample with an antibody that specifically binds
CC a SV-NGEP polypeptide and detecting the formation of an immune complex,
CC or detecting an increase in expression of SV-NGEP polypeptide or mRNA;
CC producing an immune response against a cell expressing SV-NGEP, for
CC example in a subject with prostate cancer, by administering SV-NGEP
CC polypeptide or polynucleotide to produce an immune response that
CC decreases growth of the prostate cancer; inhibiting the growth of a
CC malignant cell that expresses SV-NGEP by culturing cytotoxic T
CC lymphocytes (CTLs) with SV-NGEP to produce activated CTLs, and contacting
CC these with the malignant cell; and inhibiting the growth of a malignant
CC cell by contact with an antibody that specifically binds SV-NGEP, where
CC the antibody is linked to a chemotherapeutic agent or toxin.
XX
SQ Sequence 9 AA;

Query Match 1.2%; Score 9; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. No. 3.9e+06;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy        247 WLLSSACAL 255
              |||||||||
Db          1 WLLSSACAL 9
```

RESULT 8

ADT77667
ID   ADT77667 standard; peptide; 9 AA.
XX
AC   ADT77667;
XX
DT   13-JAN-2005  (first entry)
XX
DE   Splice variant-novel gene expressed in prostate (SV-NGEP) epitope.
XX
KW   Splice variant-novel gene expressed in prostate; SV-NGEP; human;
KW   prostate cancer; cytostatic; gene therapy; immunotherapy; epitope.
XX
OS   Homo sapiens.
XX
PN   WO2004092213-A1.
XX
PD   28-OCT-2004.
XX
PF   05-APR-2004; 2004WO-US010588.
XX
PR   08-APR-2003; 2003US-0461399P.
XX
PA   (USSH ) US DEPT HEALTH & HUMAN SERVICES.
XX
PI   Pastan I,  Bera TK,  Lee B;
XX
DR   WPI; 2004-758338/74.
XX
PT   New Splice Variant-Novel Gene Expressed in Prostate polypeptide or
PT   encoding nucleic acid molecule for diagnosing, preventing or treating
PT   cancer, especially prostate cancer.
XX
PS   Disclosure; SEQ ID NO 4; 88pp; English.
XX
CC   The present sequence is that of a predicted epitope of human splice
CC   variant-novel gene expressed in prostate (SV-NGEP) ADT77664. The epitope
CC   is predicted to bind HLA2-01 and was identified using an HLA binding
CC   motif program. It corresponds to amino acids 215-223 of SV-NGEP.
CC   Polypeptides comprising an immunogenic fragment of 8 consecutive amino
CC   acids of SV-NGEP which specifically bind to an antibody that specifically
CC   binds a polypeptide comprising amino acids 157-933 of SV-NGEP are
CC   claimed. The invention provides methods for: detecting prostate cancer in
CC   a subject by contacting a sample with an antibody that specifically binds
CC   a SV-NGEP polypeptide and detecting the formation of an immune complex,
CC   or detecting an increase in expression of SV-NGEP polypeptide or mRNA;
CC   producing an immune response against a cell expressing SV-NGEP, for
CC   example in a subject with prostate cancer, by administering SV-NGEP
CC   polypeptide or polynucleotide to produce an immune response that
CC   decreases growth of the prostate cancer; inhibiting the growth of a

CC malignant cell that expresses SV-NGEP by culturing cytotoxic T
CC lymphocytes (CTLs) with SV-NGEP to produce activated CTLs, and contacting
CC these with the malignant cell; and inhibiting the growth of a malignant
CC cell by contact with an antibody that specifically binds SV-NGEP, where
CC the antibody is linked to a chemotherapeutic agent or toxin.
XX
SQ Sequence 9 AA;

Query Match 1.2%; Score 9; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. No. 3.9e+06;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy         59 VLLEVVPDV 67
              |||||||||
Db          1 VLLEVVPDV 9
```

RESULT 9
AAG95042
ID AAG95042 standard; peptide; 10 AA.
XX
AC AAG95042;
XX
DT 18-SEP-2001 (first entry)
XX
DE Human complementary peptide, SEQ ID NO: 1236.
XX
KW Human; complementary peptide; ligand; drug discovery; drug design.
XX
OS Homo sapiens.
XX
PN WO200142277-A2.
XX
PD 14-JUN-2001.
XX
PF 13-DEC-2000; 2000WO-GB004776.
XX
PR 13-DEC-1999; 99GB-00029464.
XX
PA (PROT-) PROTEOM LTD.
XX
PI Roberts GW, Heal JR;
XX
DR WPI; 2001-408419/43.
XX
PT A set of peptide ligands consisting of specific complementary peptides to
PT proteins encoded by genes of the human genome, useful in an assay for
PT screening and identifying of one or more novel peptides which are drug
PT candidates or pro-drugs.

XX
PS Example 4; Page 217; 646pp; English.
XX
CC The invention relates to a set of complementary peptide ligands generated
CC from the human genome. The complementary peptides interact with their
CC relevant target proteins encoded in the human genome. They can be used as
CC reagents in drug discovery and as lead ligands to facilitate drug design
CC and development. The present sequence is a complementary peptide provided
CC in the specification
XX
SQ Sequence 10 AA;

Query Match 1.0%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 8.6;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy        525 AGASAGAS 532
              ||||||||
Db          1 AGASAGAS 8
```

RESULT 10
AAG97554
ID AAG97554 standard; peptide; 10 AA.
XX Does not bind MHC /LBG/
AC AAG97554;
XX
DT 18-SEP-2001 (first entry)
XX
DE Human complementary peptide, SEQ ID NO: 3749.
XX
KW Human; complementary peptide; ligand; drug discovery; drug design.
XX
OS Homo sapiens.
XX
PN WO200142277-A2.
XX
PD 14-JUN-2001.
XX
PF 13-DEC-2000; 2000WO-GB004776.
XX
PR 13-DEC-1999; 99GB-00029464.
XX
PA (PROT-) PROTEOM LTD.
XX
PI Roberts GW, Heal JR;
XX
DR WPI; 2001-408419/43.
XX

PT A set of peptide ligands consisting of specific complementary peptides to
PT proteins encoded by genes of the human genome, useful in an assay for
PT screening and identifying of one or more novel peptides which are drug
PT candidates or pro-drugs.
XX
PS Example 6; Page 581; 646pp; English.
XX
CC The invention relates to a set of complementary peptide ligands generated
CC from the human genome. The complementary peptides interact with their
CC relevant target proteins encoded in the human genome. They can be used as
CC reagents in drug discovery and as lead ligands to facilitate drug design
CC and development. The present sequence is a complementary peptide provided
CC in the specification
XX
SQ Sequence 10 AA;

Query Match 1.0%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 8.6;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy        525 AGASAGAS 532
              ||||||||
Db          1 AGASAGAS 8
```

RESULT 11
AAG97553
ID AAG97553 standard; peptide; 10 AA.
XX
AC AAG97553; Does not bind MHC /LBG/
XX
DT 18-SEP-2001 (first entry)
XX
DE Human complementary peptide, SEQ ID NO: 3748.
XX
KW Human; complementary peptide; ligand; drug discovery; drug design.
XX
OS Homo sapiens.
XX
PN WO200142277-A2.
XX
PD 14-JUN-2001.
XX
PF 13-DEC-2000; 2000WO-GB004776.
XX
PR 13-DEC-1999; 99GB-00029464.
XX
PA (PROT-) PROTEOM LTD.
XX

PI Roberts GW, Heal JR;
XX
DR WPI; 2001-408419/43.
XX
PT A set of peptide ligands consisting of specific complementary peptides to
PT proteins encoded by genes of the human genome, useful in an assay for
PT screening and identifying of one or more novel peptides which are drug
PT candidates or pro-drugs.
XX
PS Example 6; Page 581; 646pp; English.
XX
CC The invention relates to a set of complementary peptide ligands generated
CC from the human genome. The complementary peptides interact with their
CC relevant target proteins encoded in the human genome. They can be used as
CC reagents in drug discovery and as lead ligands to facilitate drug design
CC and development. The present sequence is a complementary peptide provided
CC in the specification
XX
SQ Sequence 10 AA;

Query Match 1.0%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 8.6;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy        525 AGASAGAS 532
              ||||||||
Db          1 AGASAGAS 8
```

Search completed: March 17, 2009, 20:59:10
Job time : 136 secs